Aetna modified CPB 0547 for rosacea treatment coverage, effective September 26, 2025. Here's what changes for billing teams.
Aetna, a CVS Health company, updated Clinical Policy Bulletin CPB 0547 governing rosacea treatment. The revision clarifies medical necessity criteria for surgical rhinophyma treatment, confirms coverage for topical oxymetazoline (Rhofade) for persistent facial erythema, and draws a hard line between covered medical treatment and non-covered cosmetic procedures. The codes most directly affected include CPT 30120 for rhinophyma excision, CPT 10040 for acne surgery, and HCPCS codes J0585–J0589 for botulinum toxin injections. If your dermatology or plastic surgery billing team hasn't reviewed this update, do it before claims start hitting that September 26 effective date.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna |
| Policy | Rosacea — CPB 0547 |
| Policy Code | CPB 0547 |
| Change Type | Modified |
| Effective Date | September 26, 2025 |
| Impact Level | Medium |
| Specialties Affected | Dermatology, Plastic Surgery, Otolaryngology, Primary Care |
| Key Action | Audit rhinophyma and telangiectasia claims for medical necessity documentation before billing CPT 30120 or destruction codes |
Aetna Rosacea Coverage Criteria and Medical Necessity Requirements 2025
The Aetna rosacea coverage policy draws a clear line between two categories: medical treatment and surgical treatment of disfigurement. Medical treatment of rosacea is medically necessary. Surgical treatment of cosmetic disfigurement — think laser removal of telangiectasias, dermabrasion for scarring, or chemical peels — is not.
That distinction sounds clean until your billing team is staring at a rhinophyma case. Aetna considers excision or surgical planing of rhinophyma (CPT 30120) medically necessary only under two specific conditions. The patient must have bleeding refractory to medical therapy — meaning repeated cautery of bleeding telangiectasias hasn't solved the problem — or infection refractory to medical therapy, meaning frequent antibiotic courses for pustular eruptions haven't controlled the condition.
"Refractory to medical therapy" is doing a lot of work in this policy. Document the failed treatments explicitly before billing CPT 30120. Aetna will want to see that conservative approaches were tried and didn't hold.
For topical oxymetazoline (Rhofade), Aetna's coverage policy confirms medical necessity for adults with persistent facial erythema associated with rosacea. This one is relatively straightforward. Pair the claim with ICD-10 L71.x for rosacea or L53.9 for erythematous condition, unspecified, depending on how the diagnosis is documented.
When asking whether Aetna rosacea reimbursement applies to a specific procedure, the first question is always: is this treating a functional or medical problem, or correcting appearance? That test runs through every section of CPB 0547 in the CPB 0547 Aetna system.
Aetna Rosacea Exclusions and Non-Covered Indications
This is where Aetna rosacea billing gets complicated fast.
Surgical treatment of disfigurement from rosacea — scarring, telangiectasias — is cosmetic under this coverage policy. That means CPT codes for laser destruction (17106, 17107, 17108), dermabrasion (15780–15783), and chemical peels (15788, 15789, 15792, 15793) are not covered when the clinical indication is cosmetic correction of rosacea-related disfigurement.
Botulinum toxin injections (HCPCS J0585, J0586, J0587, J0588, J0589) fall into the non-covered group under this policy as well. Aetna does not consider botulinum toxin for rosacea-related indications to meet medical necessity criteria here. If your team has been billing any of these J-codes for rosacea, stop and audit those claims immediately.
Reflectance confocal microscopy codes — CPT 96931, 96932, 96933, and add-on codes 96934, 96935, 96936 — are also excluded. So are platelet-rich plasma injections (CPT 0232T). Neither meets Aetna's criteria under CPB 0547.
The lab codes in this policy — CPT 82247, 82248 (bilirubin), and 84550 (uric acid) — are listed as non-covered for rosacea indications. These are sometimes ordered in the context of H. pylori workup adjacent to rosacea treatment, but Aetna draws them outside covered indications under this policy.
The real claim denial risk here is miscoding cosmetic disfigurement treatment as a medically necessary procedure. One wrong modifier or a vague diagnosis code will kick that claim back.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Medical treatment of rosacea | Covered | L71.0–L71.9 | Standard medical management; medical necessity applies |
| Excision/shaving of rhinophyma — bleeding refractory to medical therapy | Covered | CPT 30120, L71.1 | Must document failed cautery of bleeding telangiectasias |
| Excision/shaving of rhinophyma — infection refractory to medical therapy | Covered | CPT 30120, L71.1 | Must document repeated antibiotic courses for pustular eruptions |
| Topical oxymetazoline (Rhofade) for persistent facial erythema | Covered | L53.9, L71.x | Adults only; persistent facial erythema associated with rosacea |
| Acne surgery (CPT 10040) when criteria met | Covered | CPT 10040 | Selection criteria apply |
| Surgical treatment of telangiectasias/scarring from rosacea | Not Covered (Cosmetic) | CPT 17106–17108, 15780–15783, 15788–15793 | Disfigurement treatment classified as cosmetic |
| Botulinum toxin injections for rosacea | Not Covered | HCPCS J0585–J0589 | Excluded under CPB 0547 |
| Platelet-rich plasma injection (CPT 0232T) | Not Covered | CPT 0232T | Not covered for rosacea indication |
| Reflectance confocal microscopy (CPT 96931–96936) | Not Covered | CPT 96931–96936 | Excluded under this policy |
| Dermabrasion for rosacea scarring | Not Covered (Cosmetic) | CPT 15780–15783 | Cosmetic disfigurement treatment |
| Chemical peels for rosacea | Not Covered (Cosmetic) | CPT 15788–15793 | Cosmetic disfigurement treatment |
| Bilirubin/uric acid lab testing for rosacea workup | Not Covered | CPT 82247, 82248, 84550 | Outside covered indications under CPB 0547 |
| H. pylori therapy/zonulin measurement | Not Covered | Multiple | Not covered for rosacea under this policy |
Aetna Rosacea Billing Guidelines and Action Items 2025
| # | Action Item |
|---|---|
| 1 | Audit all open rhinophyma claims before September 26, 2025. If your team is billing CPT 30120, confirm that the chart documents failure of medical therapy — specifically repeated cautery for bleeding telangiectasias or multiple antibiotic courses for pustular eruptions. Without that documentation, Aetna has grounds for a claim denial. |
| 2 | Pull any queued claims for botulinum toxin (J0585–J0589) billed against rosacea diagnoses. These are not covered under CPB 0547. Submitting them will generate denials. If the patient's plan documents show a different indication that might qualify, loop in your compliance officer before submitting. |
| 3 | Update your charge capture to flag CPT 17106, 17107, 17108 when paired with L71.x or I78.x diagnosis codes. Laser destruction of telangiectasias is cosmetic under this coverage policy. Billing those codes for rosacea disfigurement is an automatic denial risk. |
| 4 | Confirm diagnosis coding for Rhofade (oxymetazoline) claims. Use L53.9 for persistent facial erythema or a specific L71.x rosacea code. L90.5 (scar conditions) is not the right pairing here — that maps to a cosmetic indication. |
| 5 | Remove CPT 0232T, 96931–96936, and dermabrasion/chemical peel codes from rosacea order sets. If these codes appear in any EHR templates linked to rosacea diagnosis codes, clean them out now. They are non-covered under this policy and will trigger denials. |
| 6 | Verify prior authorization requirements for CPT 30120 before scheduling rhinophyma surgery. The policy establishes medical necessity criteria, but prior authorization rules depend on the patient's specific plan. Don't assume medical necessity documentation alone is sufficient — check PA requirements before the procedure. |
| 7 | Train your front-end team on the medical vs. cosmetic distinction. Patients with rosacea-related telangiectasias or scarring frequently ask about laser treatment. Your team needs to communicate clearly that Aetna classifies surgical correction of those as cosmetic — and that means no coverage. Getting that conversation right at intake prevents billing disputes later. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Rosacea Under CPB 0547
Covered CPT Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 10040 | CPT | Acne surgery (e.g., marsupialization, opening or removal of multiple milia, comedones, cysts, pustules) |
| 30120 | CPT | Excision or surgical planing of skin of nose for rhinophyma — covered for bleeding or infection refractory to medical therapy |
Not Covered / Experimental CPT Codes
| Code | Type | Description | Reason |
|---|---|---|---|
| 0232T | CPT | Injection(s), platelet-rich plasma, any site, including image guidance, harvesting and preparation | Not covered for rosacea under CPB 0547 |
| 15780 | CPT | Dermabrasion; total face (e.g., for acne scarring, fine wrinkling, rhytids, general keratosis) | Cosmetic disfigurement treatment |
| 15781 | CPT | Dermabrasion; segmental, face | Cosmetic disfigurement treatment |
| 15782 | CPT | Dermabrasion; regional other than face | Cosmetic disfigurement treatment |
| 15783 | CPT | Dermabrasion; superficial, any site (e.g., tattoo removal) | Cosmetic disfigurement treatment |
| 15788 | CPT | Chemical peel, facial; epidermal | Cosmetic disfigurement treatment |
| 15789 | CPT | Chemical peel, facial; dermal | Cosmetic disfigurement treatment |
| 15792 | CPT | Chemical peel, nonfacial; epidermal | Cosmetic disfigurement treatment |
| 15793 | CPT | Chemical peel, nonfacial; dermal | Cosmetic disfigurement treatment |
| 17000 | CPT | Destruction of premalignant lesions, first lesion | Not covered for rosacea cosmetic indications |
| +17003 | CPT | Destruction, second through 14 lesions, each | Not covered for rosacea cosmetic indications |
| 17004 | CPT | Destruction of premalignant lesions, 15 or more | Not covered for rosacea cosmetic indications |
| 17106 | CPT | Destruction of cutaneous vascular proliferative lesions; less than 10 sq cm | Cosmetic — telangiectasias/scarring from rosacea |
| 17107 | CPT | Destruction of cutaneous vascular proliferative lesions; 10.0 to 50.0 sq cm | Cosmetic — telangiectasias/scarring from rosacea |
| 17108 | CPT | Destruction of cutaneous vascular proliferative lesions; over 50.0 sq cm | Cosmetic — telangiectasias/scarring from rosacea |
| 17110 | CPT | Destruction of benign lesions other than skin tags or cutaneous vascular lesions, up to 14 lesions | Not covered for rosacea cosmetic indications |
| 17111 | CPT | Destruction of benign lesions other than skin tags or cutaneous vascular lesions, 15 or more lesions | Not covered for rosacea cosmetic indications |
| 17340 | CPT | Cryotherapy (CO2 slush, liquid N2) for acne | Not covered for rosacea under this policy |
| 17360 | CPT | Chemical exfoliation for acne (e.g., acne paste, acid) | Not covered for rosacea under this policy |
| 82247 | CPT | Bilirubin; total | Outside covered indications under CPB 0547 |
| 82248 | CPT | Bilirubin; direct | Outside covered indications under CPB 0547 |
| 84550 | CPT | Uric acid; blood | Outside covered indications under CPB 0547 |
| 96931 | CPT | Reflectance confocal microscopy (RCM); image acquisition and interpretation, first lesion | Not covered under CPB 0547 |
| 96932 | CPT | RCM; image acquisition only, first lesion | Not covered under CPB 0547 |
| 96933 | CPT | RCM; interpretation and report only, first lesion | Not covered under CPB 0547 |
| +96934 | CPT | RCM; image acquisition and interpretation, each additional lesion | Not covered under CPB 0547 |
| +96935 | CPT | RCM; image acquisition only, each additional lesion | Not covered under CPB 0547 |
| +96936 | CPT | RCM; interpretation and report only, each additional lesion | Not covered under CPB 0547 |
Not Covered HCPCS Codes
| Code | Type | Description | Reason |
|---|---|---|---|
| J0585 | HCPCS | Injection, onabotulinumtoxinA, 1 unit | Not covered for rosacea under CPB 0547 |
| J0586 | HCPCS | Injection, abobotulinumtoxinA, 5 units | Not covered for rosacea under CPB 0547 |
| J0587 | HCPCS | Injection, rimabotulinumtoxinB, 100 units | Not covered for rosacea under CPB 0547 |
| J0588 | HCPCS | Injection, incobotulinumtoxinA, 1 unit | Not covered for rosacea under CPB 0547 |
| J0589 | HCPCS | Injection, daxibotulinumtoxina-lanm, 1 unit | Not covered for rosacea under CPB 0547 |
Key ICD-10-CM Diagnosis Codes
| Code | Description |
|---|---|
| I78.0–I78.9 | Disease of capillaries — telangiectasias and scarring from rosacea (note: maps to cosmetic/non-covered surgical indications) |
| L53.9 | Erythematous condition, unspecified — use for persistent facial erythema (Rhofade coverage) |
| L71.0 | Perioral dermatitis |
| L71.1 | Rhinophyma |
| L71.2 | Rosacea |
| L71.3 | Rosacea |
| L71.4 | Rosacea |
| L71.5 | Rosacea |
| L71.6 | Rosacea |
| L71.7 | Rosacea |
| L71.8 | Other rosacea |
| L71.9 | Rosacea, unspecified |
| L90.5 | Scar conditions and fibrosis of skin from rosacea (cosmetic indication — surgical treatment not covered) |
Get the Full Picture for CPT 30120
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.